CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Douglas Love, president and CEO of Annexon Biosciences, discusses the company’s phase 3 program in geographic atrophy.
According to Love, the primary endpoint of the program is visual acuity, “which in effect means we have slowed disease worsening in patients and allowed them to preserve their vision for longer.”
Annexon anticipates a data readout in 2026.